
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sirolimus,Paclitaxel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $4.0 million
Deal Type : Series A Financing
Details : The financing will be used to accelerate clinical development of next-generation SirPlux duo drug-coated balloon (DCB) which combines the synergistic power of sirolimus and paclitaxel to create a next-generation, front-line therapy for treating de novo c...
Product Name : SirPlux Duo DCB
Product Type : Antibiotic
Upfront Cash : Undisclosed
August 22, 2023
Lead Product(s) : Sirolimus,Paclitaxel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $4.0 million
Deal Type : Series A Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Paclitaxel,Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $7.2 million
Deal Type : Series A Financing
Advanced NanoTherapies Announces Closing of Oversubscribed $7.2 Million Series A Financing
Details : Funds will be used to complete the first-in-human clinical study in Australia of the SirPlux Duo (paclitaxel and sirolimus) drug-coated balloon (DCB) in de-novo coronary artery disease (CAD) lesions.
Product Name : SirPlux Duo
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
June 28, 2022
Lead Product(s) : Paclitaxel,Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $7.2 million
Deal Type : Series A Financing
